Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2012
11/22/2012WO2012158413A2 Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors
11/22/2012WO2012158399A1 Condensed 2 - carbamoylpyridazinones as potassium channel modulators
11/22/2012WO2012158117A1 Combination therapies for treating pain
11/22/2012WO2012157790A1 Composition containing ginseng berry extract for activating mitochondria
11/22/2012WO2012157746A1 Therapeutic drug for autoimmune disease
11/22/2012WO2012157612A1 Cell differentiation inducer and differentiation inducing method
11/22/2012WO2012157479A1 Ctrp6 which can be used as therapeutic and prophylactic agent for autoimmune diseases
11/22/2012WO2012156979A1 A water soluble composition comprising curcumin having enhanced bioavailability and process thereof
11/22/2012WO2012156968A2 Use of mesenchymal stem cells for the improvement of affective and cognitive function
11/22/2012WO2012156931A1 Hypophosphorous acid derivatives having antihyperalgic activity and biological applications thereof
11/22/2012WO2012156731A1 Honey composition with l-alanyl- l- glutamine
11/22/2012WO2012156676A1 Monoclinic crystalline form of asenapine maleate with a specific particle size distribution
11/22/2012WO2012156666A1 Prion protein antibodies for the treatment of alzheimer's disease
11/22/2012WO2012156497A1 Use of sigma ligands in diabetes type-2 associated pain
11/22/2012WO2012156384A1 Novel crystalline salts of asenapine
11/22/2012WO2012156383A1 Novel crystalline salts of asenapine with organic di-acids and tri-acids
11/22/2012WO2012156382A1 Novel crystalline asenapine hydrochloride salt forms
11/22/2012WO2012156317A2 Intranasal pharmaceutical dosage forms comprising naloxone
11/22/2012WO2012156309A1 Antibodies against her3
11/22/2012WO2012156308A1 High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain
11/22/2012WO2012156284A1 1,3-oxazines as bace1 and/or bace2 inhibitors
11/22/2012WO2012156225A1 Use of a sulfurated compound for the treatment of hyper-homocysteinemia.
11/22/2012WO2012155834A1 Preparation method for rivastigmine, intermediates thereof, and preparation method for said intermediates
11/22/2012WO2012131656A3 Compounds for use as therapeutic agents affecting p53 expression and/or activity
11/22/2012WO2012087180A9 Method for treating acute cerebral and spinal blood flow disorders of an ischaemic or haemorrhagic nature
11/22/2012WO2011093742A8 Agent for treating parkinson's disease
11/22/2012US20120296403 Methods and compounds for muscle growth
11/22/2012US20120296088 Synthesis of udp-glucose: n-acylsphingosine glucosyl transferase inhibitors
11/22/2012US20120296072 N-terminally chemically modified protein compositions and methods
11/22/2012US20120295988 Pharmaceutical Compositions of Dispersions of Amorphous Drugs Mixed with Polymers
11/22/2012US20120295981 Tetrasubstituted benzenes
11/22/2012US20120295968 Pharmaceutical Composition Comprising Cannabinoids
11/22/2012US20120295964 Retrograde transport viral vector system having envelope comprising fused glycoprotein
11/22/2012US20120295960 Treatment regimen for parkinson's disease
11/22/2012US20120295954 Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
11/22/2012US20120295952 Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
11/22/2012US20120295947 Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
11/22/2012US20120295946 Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof
11/22/2012US20120295945 Buccal, polar and non-polar spray containing ondansetron
11/22/2012US20120295942 Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists
11/22/2012US20120295938 Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
11/22/2012US20120295936 Compositions and methods for treating seizure disorders
11/22/2012US20120295924 Thienopyrimidinedione derivatives as trpa1 modulators
11/22/2012US20120295923 Aminocyclohexanes and Aminotetrahydropyrans and Related Compounds As Gamma-Secretase Modulators
11/22/2012US20120295921 Pyridyl piperidine orexin receptor antagonists
11/22/2012US20120295919 Arylpiperazine opioid receptor antagonists
11/22/2012US20120295913 Bicyclic pyrazole compounds as allosteric modulators of mglur5 receptors
11/22/2012US20120295909 Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application
11/22/2012US20120295902 Hetaryl-[1,8]naphthyridine derivatives
11/22/2012US20120295901 Novel substituted bicyclic triazole derivatives as gamma secretase modulators
11/22/2012US20120295900 1,3-oxazines as bace 1 and/or bace2 inhibitors
11/22/2012US20120295897 Spiro-oxindole compounds and their uses as therapeutic agents
11/22/2012US20120295894 Pyrrolidine compounds which inhibit beta-secretase activity and methods of use thereof
11/22/2012US20120295893 Compositions and methods of counteracting residual sedative effects of sleep/ hypnotic drugs
11/22/2012US20120295892 Gabaergic receptor subtype selective ligands and their uses
11/22/2012US20120295891 Novel substituted triazole derivatives as gamma secretase modulators
11/22/2012US20120295890 Glycosaminoglycan inhibitors
11/22/2012US20120295884 Complement pathway modulators and uses thereof
11/22/2012US20120295883 Compounds
11/22/2012US20120295882 Tricyclic Derivatives and Their Pharmaceutical Use and Compositions
11/22/2012US20120295881 Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
11/22/2012US20120295879 NK1 Antagonists
11/22/2012US20120295877 Therapeutic Compounds
11/22/2012US20120295867 Method and pharmaceutical to treat spinal discs
11/22/2012US20120295863 Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases
11/22/2012US20120295856 Fredericamycin derivatives
11/22/2012US20120295853 Neuronal pain pathway
11/22/2012US20120295852 Methods of treating depression and other related diseases
11/22/2012US20120295845 Imidazo-pyrazoles as gpr119 inhibitors
11/22/2012US20120295835 Sgef controls macular, corpus callosum and hippocampal function and development, liver homeostasis, functions of the immune system, fever response atherosclerosis and tumorogenic cell growth
11/22/2012US20120295834 Opioid Prodrugs with Heterocyclic Linkers
11/22/2012US20120294949 Methods of producing stem cell conditioned media to treat mammalian injuries or insults
11/22/2012US20120294947 Oral Preparation Having Improved Quality
11/22/2012US20120294946 Modulator
11/22/2012US20120294943 Extended-release formulation for reducing the frequency of urination and method of use thereof
11/22/2012US20120294940 Rapidly disintegrating tablet in oral cavity
11/22/2012US20120294934 Transdermal compositions for anticholinergic agents
11/22/2012US20120294907 Two or more solidifying agent-containing compositions and methods for dermal delivery of drugs
11/22/2012US20120294905 Lipid Formulated Compositions And Methods For Inhibiting Expression Of Transthyretin (TTR)
11/22/2012US20120294902 Peptide amphiphiles and methods to electrostatically control bioactivity of the ikvav peptide epitope
11/22/2012US20120294901 Novel cochleate formulations
11/22/2012US20120294895 Protein a compositions and methods of use
11/22/2012US20120294884 Methods of blocking tissue destruction by autoreactive t cells
11/22/2012US20120294880 Novel immunogenic compositions for the prevention and treatment of meningococcal disease
11/22/2012US20120294862 Antagonists of il-17a, il-17f, and il-23p19
11/22/2012US20120294854 Amino nicotinic and isonicotinic acid derivatives as dhodh inhibitors
11/22/2012US20120294850 Ganglioside Epitopes For Treating Guillain-Barre Syndrome
11/22/2012US20120294849 Use of wf10 for treating allergic asthma, allergic rhinitis and atopic dermatitis
11/22/2012US20120294844 Methods And Kits For Topical Application, Removal, And Inactivation Of Therapeutic Or Cosmetic Toxin Compositions
11/22/2012US20120294838 Regulation of endogenous gene expression in cells using zinc finger proteins
11/22/2012US20120294830 Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
11/22/2012US20120294805 DNA regulatory element for the expression of transgenes in neurons of a subject and uses thereof
11/22/2012US20120294804 Phenylethanolamine-based nmda receptor antagonists
11/22/2012US20120294802 Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
11/22/2012US20120294797 Anti-cgrp compositions and use thereof
11/22/2012US20120292797 Solid pharmaceutical dispersions with enhanced bioavailability
11/22/2012CA2836353A1 Use of sigma ligands in diabetes type-2 associated pain
11/22/2012CA2836066A1 Treatment and management of cns disorders
11/22/2012CA2835940A1 Intranasal pharmaceutical dosage forms comprising naloxone
11/22/2012CA2835835A1 Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors
1 ... 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 ... 1833